Angiogenesis Modulating Agents

Name
Angiogenesis Modulating Agents
Accession Number
DBCAT000213
Description

Agents that modulate the PHYSIOLOGIC ANGIOGENESIS process. This is accomplished by endogenous ANGIOGENIC PROTEINS and a variety of other chemicals and pharmaceutical agents.

Drugs
DrugDrug Description
BecaplerminA recombinant form of human platelet-derived growth factor used to treat ulcers due to diabetic neuropathy in the lower extremities when there is adequate blood supply to the area.
BevacizumabA monoclonal anti-vascular endothelial growth factor antibody used in combination with antineoplastic agents for the treatment of many types of cancer.
LenalidomideA thalidomide derivative used to treat multiple myeloma and anemia in low to intermediate risk myelodysplastic syndrome.
ThalidomideA medication used to treat newly diagnosed multiple myeloma and erythema nodosum leprosum.
SunitinibA receptor tyrosine kinase inhibitor and chemotherapeutic agent used for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST).
RanibizumabA recombinant humanized monoclonal antibody and VEGF-A antagonist used for the management of macular edema after retinal vein occlusion, age-related macular degeneration (wet), and diabetic macular edema.
FumagillinNot Available
HalofuginoneFor the treatment of scleroderma, cancer, and restenosis.
TetrathiomolybdateInvestigated for use/treatment in liver disease and pulmonary fibrosis.
OglufanideInvestigated for use/treatment in hepatitis (viral, C).
EndostatinInvestigated for use/treatment in cancer/tumors (unspecified), macular degeneration, and diabetic retinopathy.
SemaxanibInvestigated for use/treatment in colorectal cancer and lung cancer.
SqualamineInvestigated for use/treatment in ovarian cancer, lung cancer, and macular degeneration.
PomalidomideA thalidomide analogue used in combination with dexamethasone to treat patients with multiple myeloma.
RoquinimexRoquinimex is investigated to be used as a treatment of a number of cancers and autoimmune conditions. As well, roquinimex is researched to be used as adjuvant therapy after bone...
TrebananibTrebananib is under investigation for the treatment of Ovarian Cancer, Peritoneal Cancer, and Fallopian Tube Cancer. Trebananib has been investigated for the treatment of Cancer, Oncology, Carcinoma, Metastases, and Colon...
AnecortaveAnecortave is under investigation in clinical trial NCT00691717 (Anecortave Acetate Safety in Patients With Open-Angle Glaucoma or Ocular Hypertension).
TNP-470O-(chloroacetylcarbamoyl)fumagillol (TNP-470) has been used in trials studying the treatment of HIV Infections, Sarcoma, Kaposi, and Pancreatic Neoplasms.
VolociximabInvestigated for use/treatment in solid tumors, renal cell carcinoma, melanoma, pancreatic cancer, lung cancer, and ovarian cancer.
EndostarEndostar is under investigation for the treatment of Nasopharyngeal Carcinoma. Endostar has been investigated for the treatment of Non-small Cell Lung Cancer.
BeloranibBeloranib has been used in trials studying the treatment of Obesity, Over-weight, Type 2 Diabetes, Craniopharyngioma, and Hypothalamic Injury, among others.
Edodekin alfaEdodekin alfa is under investigation in clinical trial NCT01468896 (Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That Is Recurrent, Metastatic, or...
Drugs & Drug Targets
DrugTargetType
BecaplerminPlatelet-derived growth factor receptor betatarget
BecaplerminAlpha-2-macroglobulintarget
BecaplerminPlatelet-derived growth factor receptor alphatarget
BevacizumabVascular endothelial growth factor Atarget
BevacizumabComplement C1q subcomponent subunit Atarget
BevacizumabComplement C1q subcomponent subunit Btarget
BevacizumabComplement C1q subcomponent subunit Ctarget
BevacizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
BevacizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
LenalidomideProstaglandin G/H synthase 2target
LenalidomideTumor necrosis factor ligand superfamily member 11target
LenalidomideCadherin-5target
LenalidomideProtein cereblontarget
LenalidomideP-glycoprotein 1transporter
ThalidomideTumor necrosis factortarget
ThalidomideNuclear factor NF-kappa-B p105 subunittarget
ThalidomideProstaglandin G/H synthase 2target
ThalidomideCytochrome P450 2C19enzyme
ThalidomideCytochrome P450 2C9enzyme
ThalidomideProstaglandin G/H synthase 1enzyme
ThalidomideProstaglandin G/H synthase 2enzyme
ThalidomideCytochrome P450 3A5enzyme
ThalidomideFibroblast growth factor receptor 2target
ThalidomideDNAtarget
ThalidomideProtein cereblontarget
Thalidomidealpha1-acid glycoproteintarget
SunitinibPlatelet-derived growth factor receptor betatarget
SunitinibVascular endothelial growth factor receptor 1target
SunitinibVascular endothelial growth factor receptor 2target
SunitinibVascular endothelial growth factor receptor 3target
SunitinibMast/stem cell growth factor receptor Kittarget
SunitinibReceptor-type tyrosine-protein kinase FLT3target
SunitinibMacrophage colony-stimulating factor 1 receptortarget
SunitinibPlatelet-derived growth factor receptor alphatarget
SunitinibCytochrome P450 3A4enzyme
SunitinibCytochrome P450 3A5enzyme
SunitinibCytochrome P450 3A7enzyme
SunitinibMultidrug resistance-associated protein 4transporter
SunitinibP-glycoprotein 1transporter
SunitinibCanalicular multispecific organic anion transporter 1transporter
SunitinibATP-binding cassette sub-family G member 2transporter
RanibizumabVascular endothelial growth factor Atarget
FumagillinMethionine aminopeptidase 2target
HalofuginoneCollagen alpha-1(I) chaintarget
Halofuginone72 kDa type IV collagenasetarget
TetrathiomolybdateAmyloid beta A4 proteintarget
Endostatin72 kDa type IV collagenasetarget
EndostatinMatrix metalloproteinase-9target
EndostatinCollagenase 3target
EndostatinFocal adhesion kinase 1target
EndostatinE-selectintarget
EndostatinCytochrome P450 19A1enzyme
SemaxanibVascular endothelial growth factor receptor 2target
SemaxanibProstaglandin G/H synthase 2enzyme
PomalidomideCytochrome P450 1A2enzyme
PomalidomideCytochrome P450 3A4enzyme
PomalidomideP-glycoprotein 1transporter
PomalidomideProtein cereblontarget
PomalidomideTumor necrosis factortarget
PomalidomideProstaglandin G/H synthase 2target
TNP-470Methionine aminopeptidase 2target